Skip to main content
OpenTrials
Completed

NCT Number: NCT03365817

Cognitive Function and Addiction Under Opioid Tapering

This study evaluates the effects of opioid dose reduction in the treatment of chronic pain in adults. Participants were divided in two groups: 1) patients that reduced opioid dose and 2) patients that kept the same opioid dose for six months.

Completed

Looking for future studies?

Notify Me

Key information

About this study

BACKGROUND The indications for initiating long-term opioid treatment for chronic non-cancer pain are often unclear and may be associated with poor outcomes and problematic use. Few available studies demonstrated that opioids do not provide advantages regarding pain control, quality of life and functional capacity in this population and may have numerous serious adverse effects and consequences.

AIMS

This study aimed at:

  • evaluating the feasibility of a opioid tapering off program to patients with chronic pain,
  • investigating the influence of opioid tapering off on cognitive function, pain, symptoms of opioid withdrawal, anxiety , depression, and health related quality of life,
  • investigating the prevalence of addiction in chronic pain patients in a long-term treatment,
  • determining the predictive value of the Pain Medication Questionnaire (PMQ) in patients with chronic pain,
  • investigating how opioid tapering off influences PMQ.

METHODS

Study design

This is a prospective, single centre, open-label, parallel-group randomized controlled trial (1:1) conducted at the Multidisciplinary Pain Centre of Rigshospitalet, Copenhagen University Hospital, Denmark.

Two phases with nine assessments were planned. The Phase 1 was the stabilization phase and consisted of two assessments: the first assessment (baseline) was done when patients were admitted to the pain centre and the second assessment was done when medical treatment was considered stable for at least three weeks (stable dose levels and regular intervals). In the following patients went through Phase 2 and were randomized to receive the intervention (Taper off Group) or continue the same stable treatment (Control Group). Seven assessments were planned to this phase: third and fourth assessments were done in intervals of two to three weeks and the following assessments (fifth to ninth) with intervals of one month in between.

Intervention

The taper-off intervention consisted of a reduction of 10% of the daily opioid dose every 1-2 weeks until discontinuation of opioid treatment for up to six months. Clonidine use (25mg - 150mg/day) was allowed in cases of opioid withdrawal symptoms, according to medical prescription.

Analysis

Statistical analysis will be performed to compare baseline characteristics between groups (patients that complete the study vs. patients that dropped out and intervention vs. control group). Comparative analysis of primary and secondary outcomes between groups will also be performed to identify significant differences associated with the intervention.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age 18 years old or more
  • at least seven years of schooling
  • pain duration of at least six months,
  • treatment with oral opioids for more than three months
  • daily opioid dose ≥ 60 mg of oral morphine equivalent

Exclusion criteria

  • not fluent in Danish language
  • cancer disease
  • poor general health condition
  • pregnancy, dementia
  • encephalopathy
  • brain damage
  • cranial base trauma
  • enrolled in other studies

Treatment and study plan

Opioids taper off

Drug

Decrease of 10% of opioid daily dose every one to two weeks until discontinuation for up to six months.

Other names: Morphine, oxycodone, metadone, fentanyl, tramadol

Opioid stable treatment

Drug

No changes on prescribed opioids and adjuvant medication for the next six months

Primary outcomes

  1. Cognitive function - sustained attention

    Time frame: Through study completion up to 4 years.

    EKHO, computer program that registers the continuous reaction time to respond to the emission of a sound signal. Scores were summarized in milliseconds using 10th (fastest values), 50th and 90th (slowest values) percentiles. More prolonged times mean worse performance.

  2. Cognitive function - psychomotor speed

    Time frame: Through study completion up to 4 years.

    Finger Tapping Test, a mechanical device with a key attached was used to record the number of taps. Score was calculated by the numbers of taps, considering the average of each hand and the differences between hands. Higher scores mean better performance.

  3. Cognitive function - working memory

    Time frame: Through study completion up to 4 years.

    Digit Span Test, subjects should repeat orally series of numbers of increasing lengths, in forward and backward orders. Scores were calculated separately for forward and backward exercises, considering the number of correct repetitions. Scores range from 0 to 14. Higher scores mean better performance.

  4. Cognitive function - mental flexibility

    Time frame: Through study completion up to 4 years

    Trail Making Test B, numbers and letters written on a paper should be connected in alternated sequence and increasing order. Score was calculated by the total time spent to correctly conclude the test (seconds). Shorter time mean better performance.

  5. Cognitive function - mental state

    Time frame: Through study completion up to 4 years.

    Mini Mental State Examination, measures orientation to time and place, registration of words, attention, calculation, and word recall, as well as language and visual construction. Total scores range from 0 to 30; scores below 27 were considered indicative of cognitive dysfunction.

  6. Risk of opioid misuse

    Time frame: Through study completion up to 4 years.

    Pain Medication Questionnaire, 26 items responded on a 5-point Likert format scale. Scores range from 0 to 104, higher score means higher risk of opioid misuse. Scores equal or above 22 were considered indicative of risk for opioid addiction.

Secondary outcomes

  1. Pain intensity

    Time frame: Through study completion up to 4 years.

    Verbal numerical scale from 0=no pain to 10= worst pain, to assess pain right now and average pain.

  2. Sleep

    Time frame: Through study completion up to 4 years.

    Number of total hours of sleep in the previous night before assessment

  3. Rest

    Time frame: Through study completion up to 4 years.

    Rest sensation assessed by the question "do you feel rested?". Answers were categorized as yes or no.

  4. Quality of life

    Time frame: Through study completion up to 4 years.

    RAND 36-Item Short Form Health Survey version 1.0., 36 items distributed in 8 scales: physical functioning, bodily pain, role limitations due to physical health, role limitations due to emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. Each item was scored on a 0 to 100 range. Items in the same scale were averaged together to create the 8 scale scores. A high score defines a more favorable health state.

  5. Depression and anxiety

    Time frame: Through study completion up to 4 years.

    Hospital Anxiety and Depression Scale, self-assessment about the last week. It has 14 items divided in anxiety subscale and depression subscale with seven items each one.The maximum score for each scale is 21; cut-off scores for each scale were 8 to 10 for possible and 11 or higher for probable presence of mood disorder.

    A clinical judgment was also done by the pain specialist physician (possible answers were yes or no)

  6. Objective symptoms of opioid withdrawal

    Time frame: Through study completion up to 4 years.

    Objective Opiate Withdrawal Scale, 13 physically observable signs, rated present or absent that reflected common motoric and autonomic manifestations of opiate withdrawal: yawning, rhinorrhea, piloerection, perspiration, lacrimation, mydriasis, hands tremors, hot and cold flashes (shivering), restlessness (frequent shifts of position), vomiting. muscle twitches, abdominal cramps, and anxiety. Scores range from 0 to 13, higher scores mean more opioid withdrawal symptoms.

  7. Subjective symptoms of opioid withdrawal

    Time frame: Through study completion up to 4 years.

    Subjective Opiate Withdrawal Scale, self-assessment, 16 items: motoric, autonomic, gastrointestinal, and musculoskeletal opiate withdrawal symptoms and indirectly related psychological symptoms, like anxiety and craving. Answers are scored from 0 to 4 based on how patient is feeling at the time of assessment. Scores range is 0-64, higher scores mean more opioid withdrawal symptoms.

  8. Addiction - Portnoy's Criteria

    Time frame: Through study completion up to 4 years.

    Classification according to Portnoy's Criteria (psychological dependence, evidence of compulsive drug use, and evidence of a group of associated behaviors). Subjects were classified in addict and non-addict.

  9. Addiction - International Classification of Diseases -10.

    Time frame: Through study completion up to 4 years.

    Diagnostic criteria according to the International Classification of Diseases -10. Subjects should present at least three symptoms associated with addiction in the least month or several times within a year to be considered addict.

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Collaborators

  • Hørslev-Fonden
  • The Ministry of Science, Technology and Innovation, Denmark

Registry information

Official study title

Cognitive Function and Addiction in Patients With Chronic Pain Under Opioid Tapering in a Multidisciplinary Pain Treatment

Important dates

Study start
2009
Primary completion
2014
Study completion
2014
First posted
Dec 7, 2017
Registry last updated
Dec 7, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.